Treatment of HER2-positive breast cancer: current status and future perspectives

Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne(Baylor College of Medicine), Edith A. Perez(Mayo Clinic in Florida), Fabio Puglisi(University of Udine), Luca Gianni
Nature Reviews Clinical Oncology
November 29, 2011
10.1038/nrclinonc.2011.177
Cited by 870

Abstract

Related Papers

Untangling the ErbB signalling network
Yosef Yarden, Mark X. Sliwkowski|Nature Reviews Molecular Cell Biology|2001|6.9k
The discovery of receptor tyrosine kinases: targets for cancer therapy
Andreas Gschwind, Oliver M. Fischer, Axel Ullrich|Nature reviews. Cancer|2004|1.2k
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila, Robert W. Akita, Kathryn L. Parsons et al.|Cancer Cell|2009|830
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
Ronit Pinkas‐Kramarski, Lior Soussan, Hayley R. Waterman et al.|The EMBO Journal|1996|770
Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.
DJ Slamon, W. Eiermann, Nicholas J. Robert et al.|Cancer Research|2009|554